Selective targeting of multiple myeloma cancer cell

A paper published in SCIENCE TRANSLATIONAL MEDICINE on Feb 16th showed a case study of successful and efficient targeting of the multiple myeloma cancer cells via their ubiquitous protein CD98 heavy chain using a monoclonal antibody. Multiple myeloma is a cancer that forms in a class of white blood cells called plasma cells. Healthy plasma cells help fighting infections by making antibodies that recognize and attack microbes. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and reduce healthy blood cells. Multiple myeloma accounts for 1% of all cancers and is the 2^nd most common hematologic malignancy after lymphoma. The results of this study provide a powerful tool for the recognition of cancer cells and also for targeted drug delivery to the cells. For more details, read the full paper in the link below:

https://www.science.org/doi/10.1126/scitranslmed.aax7706